Business & Industry

Danish pharmaceutical major Novo Nordisk has entered into a strategic collaboration with OpenAI to embed artificial intelligence across its drug development operations, with the stated goal of accelerating the delivery of new treatments. Announced on Tuesday, the initiative is...

Regeneron Pharmaceuticals has entered into a strategic agreement with Telix Pharmaceuticals to jointly develop next-generation oncology treatments, in a deal valued at up to $2.1 billion in milestone payments. The radiopharma collaboration will combine Regeneron’s antibody-based discovery capabilities with...

Biopharma companies are continuing to redirect production strategies toward Europe, even as U.S. policymakers attempt to strengthen domestic output through tariffs and onshoring measures. According to GlobalData, the latest data highlights a clear divergence in deal activity, with drug...

DeepCyte, a techbio company focused on advancing AI Drug Toxicology, has launched with $1.5 million in seed funding. The company is introducing two integrated solutions aimed at helping biopharma teams detect, predict, and explain drug toxicity directly in human...

Halozyme Therapeutics has entered into a global exclusive partnership and licence agreement with Vertex Pharmaceuticals through its subsidiary Halozyme Hypercon, marking a new step in advancing drug delivery capabilities. The deal gives Vertex access to the Hypercon platform, which...

Gilead Sciences has agreed to acquire Germany-based Tubulis in a deal valued at $3.15 billion upfront, with an additional $1.85 billion tied to milestones, as the company advances its position in the rapidly evolving antibody-drug conjugate segment. The acquisition...

Neurocrine Biosciences is close to securing a more than $2.5bn acquisition of Soleno Therapeutics, the developer of a treatment for a rare genetic form of obesity. The talks, described as advanced, highlight how midsized drugmakers are increasingly pursuing strategic...